BACKGROUND/AIM: Trabectedin is a synthetic antineoplastic agent approved for advanced soft tissue sarcoma (STS) in Japan. The aim of this study was to evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS. PATIENTS AND METHODS: We retrospectively reviewed 38 patients with advanced STS who received salvage chemotherapy with trabectedin. RESULTS: The overall response and disease control rates were 16% (5 patients) and 67% (20 patients), respectively. The median progression-free and overall survival were 7.3 and 17.8 months, respectively. There were no significant differences between patients with liposarcoma or leiomyosarcoma and those without, or between patients with TRS and those without. The most common grade 3-4 AEs were elevated transaminases and neutropenia. CONCLUSION: Trabectedin 1.2 mg/m2, as the approved dose in Japan, showed similar efficacy to the dose of 1.5 mg/m2 used in Western countries. Trabectedin could be an option for advanced STS in Japan, regardless of histological subtype. Copyright
BACKGROUND/AIM: Trabectedin is a synthetic antineoplastic agent approved for advanced soft tissue sarcoma (STS) in Japan. The aim of this study was to evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS. PATIENTS AND METHODS: We retrospectively reviewed 38 patients with advanced STS who received salvage chemotherapy with trabectedin. RESULTS: The overall response and disease control rates were 16% (5 patients) and 67% (20 patients), respectively. The median progression-free and overall survival were 7.3 and 17.8 months, respectively. There were no significant differences between patients with liposarcoma or leiomyosarcoma and those without, or between patients with TRS and those without. The most common grade 3-4 AEs were elevated transaminases and neutropenia. CONCLUSION:Trabectedin 1.2 mg/m2, as the approved dose in Japan, showed similar efficacy to the dose of 1.5 mg/m2 used in Western countries. Trabectedin could be an option for advanced STS in Japan, regardless of histological subtype. Copyright
Authors: Emiliano Calvo; Analia Azaro; Jordi Rodon; Luc Dirix; Manon Huizing; Francis Mark Senecal; Patricia LoRusso; Lorrin Yee; Italo Poggesi; Jan de Jong; Spyros Triantos; Youn C Park; Roland E Knoblauch; Trilok V Parekh; George D Demetri; Margaret von Mehren Journal: Invest New Drugs Date: 2017-11-27 Impact factor: 3.850
Authors: Fredrik Mertens; Cristina R Antonescu; Peter Hohenberger; Marc Ladanyi; Piergiorgio Modena; Maurizio D'Incalci; Paolo G Casali; Massimo Aglietta; Thor Alvegård Journal: Semin Oncol Date: 2009-08 Impact factor: 4.929
Authors: Javier Martin-Broto; Antonio López Pousa; Ramón de Las Peñas; Xavier García Del Muro; Antonio Gutierrez; Javier Martinez-Trufero; Josefina Cruz; Rosa Alvarez; Ricardo Cubedo; Andrés Redondo; Joan Maurel; Juan A Carrasco; José A López-Martin; Ángeles Sala; José Andrés Meana; Rafael Ramos; Jordi Martinez-Serra; José A Lopez-Guerrero; Isabel Sevilla; Carmen Balaña; Ángeles Vaz; Ana De Juan; Regina Alemany; Andrés Poveda Journal: J Clin Oncol Date: 2016-05-16 Impact factor: 44.544
Authors: A Santoro; T Tursz; H Mouridsen; J Verweij; W Steward; R Somers; J Buesa; P Casali; D Spooner; E Rankin Journal: J Clin Oncol Date: 1995-07 Impact factor: 44.544